INTRODUCTION
Transcatheter ( percutaneous) pulmonary valve (TPV) implantation as an alternative to open-heart surgery for right ventricular outflow tract (RVOT) valve implantation was first described in 2000 by Bonhoeffer et al. 1 Since then multiple studies have documented the short-term benefits of TPV implantation using the Melody valved stent (Medtronic Inc, Minneapolis, Minnesota, USA) for dysfunctional RV to pulmonary artery (RV-PA) conduits. [2] [3] [4] After adequate prestenting, valved stent patency and leaflet function appear to be very competitive to other conduits. 5 6 However, infective endocarditis (IE) of the Melody valve emerges as a potential threat for long-term function. [7] [8] [9] The aim of this study is to assess the incidence of IE in Melody valved stents and to compare it with other surgically implanted conduits such as homografts and Contegra conduits.
PATIENTS AND METHODS Patient selection
This retrospective study includes all patients in the Congenital Heart Disease database of University Hospitals Leuven, a tertiary centre, who underwent a RVOT reconstruction with implantation of either a cryopreserved homograft (European Homograft Bank, Brussels, Belgium), a Contegra graft (VenPro Corporation, Irvine, California, USA, up until 2001; Medtronic Inc) or a Melody valved stent (Medtronic Inc). Implantation was performed according to standard techniques, including perprocedural IE prophylaxis with cephalosporins; none of the patients had anticoagulation or platelet inhibitors prescribed after the implantation. 5 The institutional ethics committee approved the study protocol. Exemption from informed consent was allowed for the homograft and Contegra cohort; all patients (or their parents) of the Melody cohort gave informed consent as part of an observational study imposed by the national health insurance for future reimbursement issues.
Review of records
The database for this study was locked for inclusion on 1 October 2013; follow-up was admitted until 4 March 2014. All hospital survivors of an elective implantation were included. General demographics were recorded, including underlying diagnosis, age at implantation, management prior to valve implantation, dates of the procedures, type and size of the implanted conduit, date of latest follow-up as well as explant date and type of the subsequent conduit. When IE occurred, date of diagnosis, findings preceding infection, microbiological findings, most probable entry point as well as treatment and outcome were recorded. Each IE was scored possible or definite IE according to the modified Duke criteria. 10 11
Statistical analysis
Data were tested for normal distribution. Descriptive data are presented as medians and IQR and/or minimum to maximal range where applicable. Categorical variables presented as number and percentages were compared using the Pearson's χ 2 test and the Wilcoxon signed-rank test. The Kaplan-Meier method was used to assess the survival time free from IE, whereas log-rank testing was used to compare the three groups. Annualised event rates were calculated using the total patient follow-up until either most recent cardiac evaluation, conduit explant, death or diagnosis of IE which were censored as event. Univariate and multivariate regression analyses were performed to identify predictors of IE. 
Infective endocarditis
In the Melody group, IE occurred in eight conduits (7.5%) after 1.3 years (IQR 1.2 years; range 1.1-3.6 years); according to the modified Duke criteria six were retrospectively classified as 'definite' IE and two were classified as 'possible' IE. None of the eight patients were previously diagnosed with IE. The details of the Melody patients are summarised in table 2. Seven out of eight Melody patients with IE presented with fever; one patient had a progressive gradient and received a bare stent before cultures turned positive. Three patients had a progressive gradient of which two patients needed surgery during hospitalisation because of threatening occlusion. One patient presented in septic shock with renal failure, diffuse intravascular coagulation and elevated liver enzymes. Septic pulmonary embolisms were found in two patients and diagnosed by CT. Vegetations were visualised by transthoracic echocardiography in four out of eight patients; none of the eight patients had significant valve regurgitation. Intracardiac echography was not performed.
Isolated bacteria in the Melody group were Corynebacterium pseudodiphtheriticum (1), HACEK (3), Staphylococcus aureus (1) (see online supplementary figure A), Streptococcus viridans (2) and Streptococcus sanguinis (1).
Adequate antibiotic therapy (6 weeks) sterilised the Melody valved stent in six cases. In two patients surgical replacement was needed 11 and 25 days after diagnosis. The patient who was first stented to relieve the stenosis received 6 weeks of antibiotics when cultures turned positive. A second Melody valve was implanted 10 months later and he is doing clinically well with 11 months of additional follow-up.
The most likely point of bacterial entrance was the dental mucosa after inadequate or no IE prophylaxis before dental care in two patients, intraoral wounds as a result of orthodontic intervention in two cases, surinfected tinea pedis in one patient (see online supplementary figure B) and poor personal hygiene and nail biting in one patient. IE in one patient was classified cryptogenic. In this retrospective study, it was not possible to determine the incidence of these risk factors in patients who did not develop IE. Four out of eight patients who developed IE on the Melody valve were known with psychomotor retardation, while this was only present in 19/99 (19.2%) non-IE patients (p=0.063).
IE occurred in 14 patients of the homograft group (2.4%) after 5.7 years (IQR 8.8 years; range 35 days-17.5 years). Two out of the 14 patients treated for IE had suffered IE prior to the homograft implantation.
Of the Contegra conduits, 11 got infected (20.4%) after 4.8 years (IQR 4.3 years; range 76 days-10.5 years). None of the Contegra patients with IE had suffered previously from IE. Six Contegra grafts needed an explantation within 2 months after diagnosis of IE because of conduit failure. Overall, 10 of the 11 conduits with IE were replaced.
Freedom from IE after Melody TPV replacement by KaplanMeier analysis was 84.9% at 5 years (then, 11 patients at risk (AR)) (figure 1). For the Contegra subgroup, freedom from IE was 87.8% (37 AR) at 5 years and 77.3% (25 patients AR) at 10 years. The homografts had an overall IE-free survival of Figure 1 Survival Kaplan-Meier curves depicting the probability of survival free from IE in the three studied conduits. Homograft: (top line) Contegra: (bottom line); Melody: (middle line). AR, at risk; IE, infective endocarditis. 98.7% at 5 years (343 patients AR), 97.3% at 10 years (180 AR) and 93.5% at 20 years of follow-up (27 patients AR) (log-rank test; p<0.001) (figure 1).
Regression analysis (table 3) could not withhold correlation between age ( p=0.056) or underlying cardiac diagnosis ( p=0.283) and IE. Male gender (factor 4.5) and the type of the implanted conduit (Melody factor 9.7 and Contegra factor 8.7) were significantly associated with IE, respectively, p=0.004 and p<0.001. In order to reduce the confounding effect of low age (no Melody was implanted below 4.5 years, endocarditis is very rare in small children), the statistical analysis was repeated after omitting all patients with implantation below 5 years; there was no significant difference with the first analysis.
DISCUSSION
The Melody valved stent has emerged as a valuable alternative for surgical replacement of a pulmonary conduit. Good longterm function of the Melody conduit depends on good stent function (no fracture, no recompression), good fixation of the vein wall to the stent (no hammock effect) and good leaflet function. Up to now, the Melody conduit has been implanted worldwide in over 7000 patients with very low mortality and minimal morbidity during early follow-up. 2 3 As in most treatment strategies, one can expect a gradual shift of indications from symptomatic to more prognostic, provided the valved conduit performs well during (very) long-term follow-up.
IE is a continuous risk for patients with a TPV implant. In our cohort, 8/107 patients (7.5%) developed IE with 85% freedom of IE at 5 years: the incidence was 3.0% per patientyear. Our results go along with the findings of other large series which report similar incidences of IE between 2.4% and 4.2% per patient-year after sufficient follow-up. In detail, Lurz et al Incidence of IE in other conduits in RVOT: differences, but why?
All types of conduits are vulnerable for the development of IE and some tissues or RVOT reconstructions may be more prone to infection. This study clearly demonstrates a difference of incidence of IE in RVOT conduits: it varies from 0.8% per patient-year for homografts to 2.7-3.0% per patient-year for Contegra-Melody conduits. Similar differences have been reported in non-comparative studies. Homografts both in aortic position and in RVOT have a very low incidence of IE of less than 1% per patient-year. [13] [14] [15] The incidence of IE in Contegra conduits varies. Albanesi et al 16 reported IE in Contegra grafts in 12/103 (11.6%) patients during follow-up of 7.6 years (range 1.7-12.7 years) with 88% free of IE at 5 years (incidence IE 1.6% per patient-year). Breymann et al 17 reported a 5 year survival free of IE in a cohort of 165 Contegra grafts of 92% (1.6% per patient-year). The relative high incidence of 2.7% per patient-year in our series might be related to suboptimal haemodynamic result with a high incidence of progressive obstruction at the distal anastomosis. 18 This study was not set up to identify reasons accounting for these differences. An obvious difference may be the leaflet and conduit tissue: homologous human tissue in homografts versus allograft bovine jugular tissue. Other factors such as size, RVOT reconstruction, flow patterns with high shear stress and turbulence, jet lesions or local stress, blood stasis in and around the conduit, surface characteristics, propensity of bacterial adhesion, onset of coagulation and thrombus formation, leaflet motion and redundancy need to be explored by large studies with different conduits.
Over the study period, the dental hygiene and awareness of IE have changed and improved. Although IE prophylaxis was explained to the patient and parents by the same team, patients and/or their family may be differently receptive to the information: the difference in size of the scar and the difference in discomfort after a surgical or percutaneous procedure may create a different degree of awareness and motivation. This argument may explain partially the difference of IE between homografts and Melody valves, but not for the similar high incidence between Contegra and Melody conduits.
Predisposing factors for IE on Melody valved stent
Male sex was identified in our series as a predisposing factor for IE for the whole group, as for the Melody cohort (8/8 (100%)). Men may be less performant in avoiding mucosal and skin lesions. Cheung et al 3 also reported in their series male sex as a predisposing factor. Furthermore, Buber et al 8 report previous IE, in situ stents in the RVOT and the presence of outflow tract irregularities as emerging additional risk factors.
In this series, we did not observe reactivation of a previous IE. Others have suggested that residual gradient, eccentric turbulence, pockets due to incomplete apposition, thrombus formation, tissue and tissue preparation, asymmetric or incomplete opening with redundancy of leaflet tissue to be of importance. 7 19 This study was not designed to address these issues. For the Melody cohort, only data on last evaluation and prior to IE were available: pulmonary regurgitation was rare in all patients, but an overall peak gradient of more than 40 mm Hg was present in 4/8 patients with IE and 5/99 without IE ( p<0.05). However, as gradient is a time-dependant variable, a more comprehensive study involving all annual measurements is required. This observation argues for leaving minimal gradient at the time of valved stent implantation. An important finding of our study is that IE did not occur within the first year of implantation. This makes an implantation-related infection or colonisation of an early thrombus very unlikely. Nearly all Melody patients with IE had an identifiable point of entry which probably could be avoided: oral wounds in five, one patient had poor personal hygiene with nail biting and one patient had a dermatophytosis complex. Such extenuating circumstances and other predisposing conditions were also reported previously. 7 Psychomotoric retardation was identified as a risk factor in our series. It may have contributed to the development or persistence of chronic skin or mucosa lesions.
The findings of this study strengthen the necessity of adapted strategies to reduce the incidence of IE. Before implantation of a Melody stent, the avoidance of hazardous lifestyle should be implemented, that is, good body hygiene, including good dental care and avoidance of skin lesions within reasonable limits. Antibiotic coverage prior to foreseeable episodes of significant bacteraemia appears indicated. 10 20 Until now, there are no data to support the benefit in this context, but the clinical problem and common sense mandate to emphasise these general concepts.
Outcome of the Melody valve after IE
After identification of the bacteria in several haemocultures, intravenous antibiotic treatment for 6 weeks was started. In this series, no patient needed an emergency operation; two patients had the Melody valve removed during the initial antibiotic treatment after 11 and 25 days because of progressive obstruction and one patient was later restented with repeat Melody. Five patients recovered with adequate valve function. However, the outcome spectrum post Melody implantation has been reported to be broader: an emergency operation at presentation may be required because of severe right heart failure and early and late deaths have been reported. 19 21 Late percutaneous revalvulation with a second Melody valve was performed in one patient of our series and others in the literature. Apparently, this was not associated with reactivation of IE and a good result in early follow-up. 19 
Limitations
This descriptive study is retrospective with its classic limitations; patients were not randomly selected and treated in a similar but still different time frame. Strengths of the study are the large and complete database and the long follow-up.
CONCLUSIONS
The Contegra conduit and Melody valved stents have a significantly higher incidence of IE than homografts. Nearly all Melody patients with IE had an avoidable point of entry. Adapted strategies preimplantation, perimplantation and postimplantation with optimal prophylaxis might reduce the incidence of IE to obtain desirable longevity.
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